2018

December 26, 2018
Sanofi: FDA Approves VAXELIS(TM), Sanofi and MSD's Pediatric Hexavalent Combination Vaccine
December 19, 2018
Dengvaxia® vaccine approved for prevention of dengue in Europe
December 18, 2018
Sanofi to Transfer U.S. Stock Exchange Listing to Nasdaq
November 16, 2018
Sanofi: European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness
November 11, 2018
Sanofi: ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) was associated with fewer deaths from any cause
November 7, 2018
New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial
November 6, 2018
FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
November 1, 2018
Sanofi and Denali Therapeutics to develop treatments for neurological and inflammatory diseases
October 31, 2018
Sanofi Q3 2018 Performance Confirms Return to Growth
October 19, 2018
Sanofi: FDA approves asthma indication for Dupixent® (dupilumab)
October 19, 2018
Sanofi receives positive CHMP opinion for dengue vaccine
October 16, 2018
Sanofi: Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps
October 1, 2018
Sanofi completes divestiture of Zentiva to Advent
September 28, 2018
Sanofi : FDA approves Libtayo® (cemiplimab) as first and only treatment for advanced cutaneous squamous cell carcinoma
September 28, 2018
Sanofi: Availability of the Pre-quarterly Results Communication
September 15, 2018
Sanofi: Positive Phase 3 results presented for Dupixent® (dupilumab)
September 13, 2018
Sanofi to refocus two global business units
September 12, 2018
FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events
September 4, 2018
Sanofi reaches civil settlement with US SEC
September 3, 2018
Sanofi: Cablivi(TM) (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
July 31, 2018
Online Availability of Sanofi Group's Half-Year Financial Report for 2018
July 31, 2018
Sanofi: Q2 2018 Performance Positions Sanofi for New Growth Phase
July 26, 2018
Sanofi Head of Human Resources Roberto Pucci to retire; Company names Caroline Luscombe to take over October 1st
June 29, 2018
Sanofi: Availability of the Pre-quarterly Results Communication
June 29, 2018
Sanofi: CHMP recommends approval of Cablivi(TM) (caplacizumab)
June 28, 2018
Sanofi : Sanofi and Advent finalize negotiations for the acquisition of Zentiva
June 19, 2018
Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer
June 19, 2018
Sanofi : Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure
June 13, 2018
Sanofi : Sanofi successfully prices USD 2 billion bond issue
June 11, 2018
Sanofi Launches "Action 2018", a Worldwide Employee Stock Purchase Plan
June 4, 2018
Sanofi: New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma
May 21, 2018
Sanofi: New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma
May 16, 2018
Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
May 14, 2018
Sanofi and Ablynx Announce the Successful Results of the Initial Tender Offer Period for Ablynx and Commencement of Squeeze-Out Tender Period
May 14, 2018
Sanofi and Ablynx Announce the Successful Results of the Initial Tender Offer Period for Ablynx and Commencement of Squeeze-Out Tender Period
May 2, 2018
Sanofi: Annual General Shareholders' Meeting of May 2, 2018
April 30, 2018
Sanofi: FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
April 27, 2018
Sanofi: First-quarter 2018 Business EPS(1) up 1.4% at CER
April 24, 2018
Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1
April 17, 2018
Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi's European generics business
April 12, 2018
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...
April 12, 2018
Sanofi to invest €350 million in Canadian vaccine facility
April 3, 2018
Sanofi: EMA to review Dupixent® (dupilumab) as potential treatment for inadequately controlled moderate-to-severe asthma
April 3, 2018
Sanofi: EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma
March 29, 2018
Sanofi: EMA to review sotagliflozin as potential treatment for type 1 diabetes
March 29, 2018
Previously announced Tender Offers by Sanofi to acquire Ablynx will commence on April 4, 2018
March 28, 2018
Sanofi: Availability of the Pre-quarterly Results Communication
March 15, 2018
Sanofi successfully prices EUR 8 billion of bond issues
March 10, 2018
Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need
March 10, 2018
Sanofi: Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate
March 8, 2018
Sanofi Completes Acquisition of Bioverativ Inc.
March 8, 2018
Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform
March 7, 2018
Sanofi: Filing of the 2017 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report
March 6, 2018
Sanofi's Board of Directors Proposes Appointment of Emmanuel Babeau as New Independent Director
March 2, 2018
Sanofi : FDA to review Dupixent® (dupilumab) as potential treatment for moderate-to-severe asthma
March 1, 2018
Sanofi Announces Receipt of Antitrust Clearances in Connection with the Acquisition of Ablynx
February 23, 2018
Sanofi: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Bioverativ
February 8, 2018
Sanofi Commences Tender Offer for Acquisition of Bioverativ Inc.
February 7, 2018
Sanofi Delivers 2017 Business EPS(1) in line with Guidance
January 31, 2018
Sanofi: Sanofi, DNDi seek European Medicines Agency review for sleeping sickness treatment
January 29, 2018
CORRECTION:Sanofi va acquérir Ablynx pour 3,9 milliards d'euros
January 29, 2018
Sanofi to acquire Ablynx for €3.9 Billion
January 23, 2018
Sanofi: Availability of the Pre-quarterly Results Communication
January 22, 2018
Sanofi to Acquire Bioverativ for $11.6 Billion
January 19, 2018
Sanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive Committee
January 8, 2018
Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs
January 7, 2018
Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance